<div id="readability-page-1"><div><ul> <li>In November 2025, uniQure reported that the FDA had informed the company that data from its Phase I/II AMT-130 gene therapy trial were not sufficient to support a Biologics License Application, leaving the timing of any filing uncertain.</li> <li>This FDA feedback places greater emphasis on the robustness of uniQure’s clinical data packages and could reshape perceptions of its gene therapy pipeline.</li> <li>We’ll now examine how the FDA’s stance on AMT-130’s Phase I/II data influences uniQure’s investment narrative and risk profile.</li> </ul><p>Uncover the next big thing with financially sound penny stocks that balance risk and reward.</p><h2>What Is uniQure's Investment Narrative?</h2><p>To own uniQure today, you have to believe in the long-term promise of gene therapy and in the company’s ability to turn a high-risk Huntington’s program into a viable commercial asset despite setbacks. The FDA’s recent view that AMT-130’s Phase I/II data are not enough for a BLA removes what many had seen as a key near-term catalyst and raises fresh questions about timelines, trial design and cash needs. That shifts the focus back to the breadth of the pipeline, the strength of the balance sheet after recent equity and debt financings, and management’s ability to re-engage regulators in 2026. With the share price having already reacted sharply, the central issue now is whether the re-shaped risk profile around AMT-130 still matches an investor’s tolerance for uncertainty.</p><p> However, the company’s reliance on one lead program is something investors should not ignore.  Despite retreating, uniQure's shares might still be trading above their fair value and there could be some more downside. Discover how much.</p><h2>Exploring Other Perspectives</h2><figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/bc3aa110-00cc-4dd4-ac63-560c2ef5d545/chart/quote-price?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/bc3aa110-00cc-4dd4-ac63-560c2ef5d545/chart/quote-price"/><figcaption>QURE 1-Year Stock Price Chart</figcaption></figure> <p>Five fair value estimates from the Simply Wall St Community span roughly US$54 to a very large US$382, underscoring how far apart individual views sit. You are weighing those opinions against a business where the FDA’s pushback on AMT-130 now makes regulatory clarity, rather than just clinical data, the key near-term swing factor for uniQure’s trajectory.</p><p>Explore 5 other fair value estimates on uniQure - why the stock might be a potential multi-bagger!</p><h2>Build Your Own uniQure Narrative</h2><p>Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.</p><ul><li>A great starting point for your uniQure research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.</li><li>Our free uniQure research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate uniQure's overall financial health at a glance.</li></ul><h2>Curious About Other Options?</h2><p>These stocks are moving-our analysis flagged them today. Act fast before the price catches up:</p><ul><li>Trump has pledged to &#34;unleash&#34; American oil and gas and these 22 US stocks have developments that are poised to benefit.</li><li>These 14 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.</li><li>AI is about to change healthcare. These 110 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data     and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your     financial situation. We aim to bring you long-term focused analysis driven by fundamental data.     Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.     Simply Wall St has no position in any stocks mentioned.</em></p></div></div>

SBIO

IBBQ

QURE

<p>uniQure's shares fell 9.4% after the FDA deemed the data from its Phase I/II AMT-130 gene therapy trial insufficient for a Biologics License Application, creating uncertainty around the filing timeline. This feedback raises concerns about the robustness of uniQure's clinical data and its investment narrative, particularly regarding the company's reliance on its Huntington's program. The FDA's stance shifts focus to the overall pipeline and financial health, with fair value estimates for the stock varying significantly among analysts. Investors must now reassess their risk tolerance in light of these developments.</p>

Simplywall

SPDR S&P Biotech

VanEck Biotech ETF

iShares Biotechnology ETF

ALPS Medical Breakthrough

Proshares Ultra Nasdaq Biotech

Invesco Biotechnology & Genome ETF

First Trust NYSE Arca Biotech Index Fd

Invesco Nasdaq Biotechnology ETF

Uniqure

uniQure (QURE) Is Down 9.4% After FDA Deems AMT-130 Data Insufficient for BLA Filing